SCD and Alzheimer disease: In this regard, delivery systems that are better able to selectively target genes and locations of interest, such as antisense oligonucleotides and nasal sprays, are already used in the clinic for other indications; our data supports developing such modes of administration for SCD inhibition in AD as well.